RegeneRx Competitors and Similar CompaniesClear all

RegeneRx's competitors and similar companies include PrimeCell Advanced Therapy, UCB, Genentech and Cipla.

	RegeneRx RegeneRx Biopharmaceuticals is a clinical-stage, biopharmaceutical company engaged in the design, research, and development of novel peptides targeted at diseases.	PrimeCell Advanced Therapy PrimeCell Advanced Therapy is a company that focuses on discovering biological drugs to support the regeneration of human tissues and organs.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.	Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
Founding Date	Founding Date 1982	Founding Date 2007	Founding Date 1928	Founding Date 1976	Founding Date 1935
Type	Type Public	Type Subsidiary	Type Public	Type Subsidiary	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech clinical research life sciences pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Rockville, US HQ	Locations Prague, CZ HQ Ostrava, CZ Bratislava, SK	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more	Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more
Employees	Employees 233% decrease	Employees 17	Employees 9,052	Employees 18,077	Employees 27,764
Financial
Revenue (est.)	Revenue (est.) $76.8k (FY, 2022)	Revenue (est.) Kč23.5m (FY, 2018)	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) ₹277.1b (FY, 2026)
Cost of goods	Cost of goods N/A	Cost of goods Kč14.8m (FY, 2018)	Cost of goods €1.4b (FY, 2025)	Cost of goods N/A	Cost of goods ₹95.5b (FY, 2026)
Gross profit	Gross profit N/A	Gross profit Kč8.7m (FY, 2018)	Gross profit €7.2b (FY, 2025)	Gross profit N/A	Gross profit ₹195b (FY, 2026)
Net income	Net income ($1.7m) (FY, 2022)	Net income Kč12.4m (FY, 2018)	Net income €1.6b (FY, 2025)	Net income N/A	Net income ₹38.7b (FY, 2026)